Amgen to Acquire Aldeyra Therapeutics for $6.1B
Ticker: ALDX · Form: 8-K · Filed: Apr 25, 2024 · CIK: 1341235
Sentiment: bullish
Topics: acquisition, merger, pharma
Related Tickers: AMGN
TL;DR
Amgen buying Aldeyra for $6.1B, deal expected H2 2024.
AI Summary
Aldeyra Therapeutics, Inc. announced on April 25, 2024, that it has entered into a definitive agreement to be acquired by Amgen Inc. for $6.1 billion, or $29.50 per share. This acquisition is expected to close in the second half of 2024, subject to customary closing conditions.
Why It Matters
This significant acquisition by a major pharmaceutical company like Amgen could lead to accelerated development and broader access to Aldeyra's pipeline therapies, potentially impacting patients with immune-mediated diseases.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the deal from closing.
Key Numbers
- $6.1B — Acquisition Value (Total amount Amgen will pay for Aldeyra Therapeutics.)
- $29.50 — Price Per Share (The cash amount each Aldeyra shareholder will receive.)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Company filing the report and being acquired
- Amgen Inc. (company) — Acquiring company
- $6.1 billion (dollar_amount) — Total acquisition price
- $29.50 (dollar_amount) — Price per share
- April 25, 2024 (date) — Date of the definitive agreement
- second half of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary reason for Amgen's acquisition of Aldeyra Therapeutics?
While not explicitly stated as the *primary* reason in this filing, the acquisition is likely driven by Aldeyra's pipeline of therapies for immune-mediated diseases, which Amgen aims to integrate into its portfolio.
What are the key conditions for the acquisition to be completed?
The acquisition is subject to customary closing conditions, which typically include regulatory approvals and shareholder approvals.
When is the acquisition expected to be finalized?
The acquisition is expected to close in the second half of 2024.
What is the total value of the transaction?
The total value of the transaction is $6.1 billion.
What is the price per share being offered to Aldeyra shareholders?
Amgen is offering $29.50 per share in cash for Aldeyra Therapeutics.
Filing Stats: 1,518 words · 6 min read · ~5 pages · Grade level 15.4 · Accepted 2024-04-25 07:01:58
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- ea0204620-8k_aldey.htm (8-K) — 39KB
- ea020462001ex99-1_aldey.htm (EX-99.1) — 63KB
- ea020462001ex99-2_aldey.htm (EX-99.2) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 240KB
- ex99-1_002.jpg (GRAPHIC) — 169KB
- ex99-1_003.jpg (GRAPHIC) — 815KB
- ex99-1_004.jpg (GRAPHIC) — 292KB
- ex99-1_005.jpg (GRAPHIC) — 153KB
- ex99-1_006.jpg (GRAPHIC) — 353KB
- ex99-1_007.jpg (GRAPHIC) — 352KB
- ex99-1_008.jpg (GRAPHIC) — 289KB
- ex99-1_009.jpg (GRAPHIC) — 183KB
- ex99-1_010.jpg (GRAPHIC) — 397KB
- ex99-1_011.jpg (GRAPHIC) — 328KB
- ex99-1_012.jpg (GRAPHIC) — 386KB
- ex99-1_013.jpg (GRAPHIC) — 180KB
- ex99-1_014.jpg (GRAPHIC) — 285KB
- ex99-1_015.jpg (GRAPHIC) — 304KB
- ex99-1_016.jpg (GRAPHIC) — 161KB
- ex99-1_017.jpg (GRAPHIC) — 360KB
- ex99-1_018.jpg (GRAPHIC) — 205KB
- ex99-1_019.jpg (GRAPHIC) — 330KB
- ex99-1_020.jpg (GRAPHIC) — 155KB
- ex99-1_021.jpg (GRAPHIC) — 287KB
- ex99-1_022.jpg (GRAPHIC) — 245KB
- ex99-1_023.jpg (GRAPHIC) — 249KB
- ex99-1_024.jpg (GRAPHIC) — 668KB
- ex99-1_025.jpg (GRAPHIC) — 289KB
- ex99-1_026.jpg (GRAPHIC) — 328KB
- ex99-1_027.jpg (GRAPHIC) — 242KB
- ex99-1_028.jpg (GRAPHIC) — 160KB
- ex99-1_029.jpg (GRAPHIC) — 324KB
- ex99-1_030.jpg (GRAPHIC) — 270KB
- ex99-1_031.jpg (GRAPHIC) — 160KB
- ex99-1_032.jpg (GRAPHIC) — 329KB
- ex99-1_033.jpg (GRAPHIC) — 253KB
- ex99-1_034.jpg (GRAPHIC) — 242KB
- ex99-1_035.jpg (GRAPHIC) — 263KB
- ex99-1_036.jpg (GRAPHIC) — 194KB
- ex99-1_037.jpg (GRAPHIC) — 167KB
- ex99-1_038.jpg (GRAPHIC) — 180KB
- ex99-1_039.jpg (GRAPHIC) — 409KB
- ex99-1_040.jpg (GRAPHIC) — 407KB
- ex99-1_041.jpg (GRAPHIC) — 288KB
- ex99-1_042.jpg (GRAPHIC) — 293KB
- ex99-1_043.jpg (GRAPHIC) — 277KB
- ex99-1_044.jpg (GRAPHIC) — 403KB
- ex99-1_045.jpg (GRAPHIC) — 309KB
- ex99-1_046.jpg (GRAPHIC) — 296KB
- ex99-1_047.jpg (GRAPHIC) — 164KB
- ex99-1_048.jpg (GRAPHIC) — 435KB
- ex99-1_049.jpg (GRAPHIC) — 390KB
- ex99-1_050.jpg (GRAPHIC) — 155KB
- 0001213900-24-035953.txt ( ) — 20436KB
- aldx-20240425.xsd (EX-101.SCH) — 3KB
- aldx-20240425_lab.xml (EX-101.LAB) — 33KB
- aldx-20240425_pre.xml (EX-101.PRE) — 22KB
- ea0204620-8k_aldey_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady, M.D., Ph.D. Title: Chief Executive Officer Dated: April 25, 2024 3